Summit Therapeutics (SMMT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Summit Therapeutics (NASDAQ:SMMT) in a research note released on Thursday morning. HC Wainwright currently has a $16.00 target price on the stock.

Several other equities analysts have also commented on the company. ValuEngine lowered Summit Therapeutics from a hold rating to a sell rating in a research report on Thursday, October 5th. Zacks Investment Research lowered Summit Therapeutics from a strong-buy rating to a hold rating in a research report on Wednesday, September 6th. Oppenheimer reiterated a buy rating and set a $24.00 price objective on shares of Summit Therapeutics in a research report on Monday, September 11th. Finally, Canaccord Genuity reiterated a buy rating and set a $28.00 price objective on shares of Summit Therapeutics in a research report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Summit Therapeutics currently has an average rating of Hold and an average target price of $20.25.

Shares of Summit Therapeutics (SMMT) traded up $0.29 during trading on Thursday, hitting $11.75. The stock had a trading volume of 11,447 shares, compared to its average volume of 21,941. Summit Therapeutics has a 12-month low of $7.95 and a 12-month high of $16.86.

Institutional investors have recently made changes to their positions in the company. Sphera Funds Management LTD. increased its position in shares of Summit Therapeutics by 49.3% during the 3rd quarter. Sphera Funds Management LTD. now owns 212,018 shares of the company’s stock valued at $2,654,000 after purchasing an additional 70,000 shares during the last quarter. Granite Point Capital Management L.P. increased its position in shares of Summit Therapeutics by 106.7% during the 3rd quarter. Granite Point Capital Management L.P. now owns 242,113 shares of the company’s stock valued at $3,031,000 after purchasing an additional 125,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Summit Therapeutics during the 1st quarter valued at about $267,000. Susquehanna International Group LLP bought a new position in shares of Summit Therapeutics during the 3rd quarter valued at about $1,828,000. Finally, Highbridge Capital Management LLC bought a new position in Summit Therapeutics during the 3rd quarter worth approximately $1,004,000. Hedge funds and other institutional investors own 29.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thelincolnianonline.com/2017/12/08/summit-therapeutics-smmt-receives-buy-rating-from-hc-wainwright.html.

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply